Bill Text: HI SCR227 | 2022 | Regular Session | Introduced
Bill Title: Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Spectrum: Partisan Bill (Democrat 5-0)
Status: (Introduced - Dead) 2022-03-16 - Referred to HTH. [SCR227 Detail]
Download: Hawaii-2022-SCR227-Introduced.html
|
THE SENATE |
S.C.R. NO. |
227 |
|
THIRTY-FIRST LEGISLATURE, 2022 |
|
|
|
STATE OF HAWAII |
|
|
|
|
|
|
|
|
||
|
|
||
SENATE CONCURRENT
RESOLUTION
REQUESTING THE
DEPARTMENT OF HEALTH TO CONVENE A MEDICINAL PSILOCYBIN AND PSILOCIN WORKING
GROUP TO EXAMINE THE MEDICINAL AND THERAPEUTIC EFFECTS OF PSILOCYBIN AND
PSILOCIN AND DEVELOP A LONG-TERM STRATEGIC PLAN TO ENSURE THE AVAILABILITY OF
MEDICINAL PSILOCYBIN AND PSILOCIN OR PSILOCYBIN-BASED AND PSILOCIN-BASED PRODUCTS
THAT ARE SAFE, ACCESSIBLE, AND AFFORDABLE FOR ELIGIBLE ADULT PATIENTS.
WHEREAS, mental health conditions are treated in various ways depending on the condition and can include medication, therapy, and psychosocial services; and
WHEREAS, these treatments, while effective
for certain conditions and patients, do not treat all mental health conditions;
and
WHEREAS, psilocybin and psilocin occur
naturally in certain species of mushrooms; and
WHEREAS, psilocybin and psilocin are natural
chemicals that can activate serotonin receptors in the brain; and
WHEREAS, studies conducted by nationally
and internationally recognized medical institutions indicate that psilocybin and
psilocin have shown efficacy, tolerability, and safety in the treatment of a
variety of mental health conditions, including addiction, depression, anxiety disorders,
and end-of-life psychological distress; and
WHEREAS, the United States Food and Drug
Administration has determined that preliminary clinical evidence indicates that
psilocybin and psilocin may demonstrate substantial improvement over available therapies
for major depressive disorder and severe treatment-resistant depression and has
granted a breakthrough therapy designation for a treatment that uses psilocybin
and psilocin as a therapy these mental health conditions; and
WHEREAS, Hawaii has a shortage of mental
health professionals and should actively consider novel, innovative, and safe
solutions to treat its citizens; now, therefore,
BE IT RESOLVED by the Senate of the Thirty-first
Legislature of the State of Hawaii, Regular Session of 2022, the House of
Representatives concurring, that the Department of Health is requested to
convene a Medicinal Psilocybin and Psilocin Working Group, to be placed in the
Department of Health for administrative purposes; and
BE IT FURTHER RESOLVED that the Medicinal Psilocybin
and Psilocin Working Group is requested to examine:
(1) Federal,
state, and local laws, regulations, administrative rules, and procedures
regarding the medicinal use of psilocybin and psilocin;
(2) Available
medical, psychological, and scientific studies, research, and other information
relating to the safety and efficacy of psilocybin and psilocin in treating
mental health conditions; and
(3) Requirements,
specifications, and guidelines for a medical professional to prescribe and
provide psilocybin and psilocin to patients; and
BE IT FURTHER RESOLVED that, if feasible, the
Medicinal Psilocybin and Psilocin Working Group is requested to develop a long-term
strategic plan to ensure the availability of medicinal psilocybin and psilocin or
psilocybin-based and psilocin-based products that are safe, accessible, and
affordable for adults twenty-one years of age or older; and
BE IT FURTHER RESOLVED that the following
individuals, or their respective designees, are requested to serve as members
of the Medicinal Psilocybin and Psilocin Working Group:
(1) The
Director of Health, who is requested to serve as chair of the working group;
(2) The
Attorney General;
(3) Faculty
members from the University of Hawaii System with relevant scientific expertise;
(4) The
chairs of the Senate and House of Representatives standing committees whose subject
matter purview is primarily responsible for reviewing legislation relating to health
and the Judiciary;
(5) A
clinical practitioner licensed to prescribe psychotropic medication in the State
of Hawaii;
(6) A
representative of the Drug Policy Forum of Hawaii, to be invited by the chair
of the working group;
(7) A
representative of the Clarity Project, to be invited by the chair of the working
group;
(8) A
representative of the Hawaii Psychiatric Medical Association, to be invited by
the chair of the working group; and
(9) A
representative of the public with psychedelics‑related industry experience,
to be invited by the chair of the working group; and
BE IT FURTHER RESOLVED that the chair of
the Medicinal Psilocybin and Psilocin Working Group may invite other interested
parties with relevant experience to join the working group, provided that the working
group does not exceed fifteen members; and
BE IT FURTHER RESOLVED that the Medicinal Psilocybin
and Psilocin Working Group is requested to submit a preliminary report of its
findings and recommendations to the Legislature no later than twenty days prior
to the convening of the Regular Session of 2023, and a final report of its
findings and recommendations, including any proposed legislation, to the
Legislature no later than twenty days prior to the convening of the Regular
Session of 2024; and
BE IT FURTHER RESOLVED that the Medicinal Psilocybin
and Psilocin Working Group be dissolved on July 1, 2024; and
BE IT FURTHER RESOLVED that certified copies of this Concurrent Resolution be transmitted to the Director of Health, Attorney General, and President of the University of Hawaii.
|
|
OFFERED BY: |
_____________________________ |
|
|
|
|
Medical Psilocybin and Psilocin Working Group; Department of Health
